바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.68 No.5
Citation Share

A Case of Delayed Severe Hypersensitivity Reaction during Genexol-PMⓇ Infusion

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2010, v.68 no.5, pp.294-297










& (2010). A Case of Delayed Severe Hypersensitivity Reaction during Genexol-PMⓇ Infusion. Tuberculosis & Respiratory Diseases, 68(5), 294-297.
  • Downloaded
  • Viewed
PDF Download

Abstract

Although TaxolⓇ is one of the most successful drugs in current cancer chemotherapy against solid tumors, a major problem is hypersensitivity reactions that arises as a consequence of activation of the complement (C) system, “C activation-related pseudo-allergy”. Most severe hypersenstivity reactions occur within the first few minutes of TaxolⓇ administration, usually after the first or second dose. Here we report a case of a severe hypersensitivity reaction in a 72-year-old man undergoing Genexol-PMⓇ infusion. Hypotension and polymorphic pruritic skin rash appeared 2 hours after the start of Genexol-PMⓇ infusion (with an appropriate premedication). Treating with methylprednisolone, epinephrine and inotropic agents, reduced the hypotension and the skin rash disappeared. We report this case with a review of the literature.

keywords
Hypersensitivity, Delayed, Anaphylaxis, Purpura, Paclitaxel, Hypersensitivity, Delayed, Anaphylaxis, Purpura, Paclitaxel

Reference

1.

1. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.Br J Cancer 2004;90:304-5.

2.

2. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009;102:179-87.

3.

3. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.Clin Cancer Res 2004;10:3708-16.

4.

4. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:2009-14.

5.

5. Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H,Hirakawa T, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.Cancer Chemother Pharmacol 2005;56:91-6.

6.

6. Ring J, Seifert J, Messmer K, Brendel W. Anaphylactoid reactions due to hydroxyethyl starch infusion. Eur Surg Res 1976;8:389-99.

7.

7. Gilbar P, Ridge A. Dexamethasone prophylaxis for paclitaxel hypersensitivity. J Oncol Pharm Pract 2002;8:81-7.

8.

8. Szebeni J. Complement activation-related pseudoallergy:a new class of drug-induced acute immune toxicity.Toxicology 2005;216:106-21.

9.

9. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A,Danino D, et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001;1:721-35.

10.

10. Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006;13:328-37.

11.

11. Szebeni J, Baranyi L, Savay S, Lutz HU, Jelezarova E.Bunger R, et al. The role of complement activation in hypersensitivity to PEGylated liposomal doxorubicin (DoxilⓇ). J Liposome Res 2000;10:467-81.

12.

12. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191-202.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy